Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 2,784 Shares

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 2,784 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $50.00, for a total value of $139,200.00. Following the transaction, the director now owns 295,810 shares of the company’s stock, valued at approximately $14,790,500. This represents a 0.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Pro-Dex Stock Down 0.4 %

Shares of NASDAQ PDEX opened at $49.41 on Thursday. The company has a quick ratio of 1.44, a current ratio of 2.58 and a debt-to-equity ratio of 0.33. The business’s 50 day moving average is $40.02 and its two-hundred day moving average is $39.68. Pro-Dex, Inc. has a 52-week low of $16.84 and a 52-week high of $59.60. The firm has a market cap of $161.13 million, a price-to-earnings ratio of 24.58 and a beta of 0.68.

Pro-Dex (NASDAQ:PDEX) last posted its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. Research analysts predict that Pro-Dex, Inc. will post 2 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its stake in Pro-Dex by 2.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after buying an additional 529 shares during the period. FMR LLC increased its position in shares of Pro-Dex by 34.9% during the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after acquiring an additional 1,028 shares during the period. Renaissance Technologies LLC raised its stake in shares of Pro-Dex by 8.1% in the fourth quarter. Renaissance Technologies LLC now owns 14,740 shares of the medical instruments supplier’s stock valued at $689,000 after acquiring an additional 1,100 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Pro-Dex by 9.1% in the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after purchasing an additional 2,296 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in Pro-Dex during the 4th quarter worth $202,000. Hedge funds and other institutional investors own 15.28% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.